Wolters Kluwer Health Partners with Emmi Solutions to Offer Integrated Patient Education

HUDSON, Ohio--Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that its Lexicomp Integrated Patient Education solution has been integrated into EmmiEngage, a patient engagement platform offered by Emmi™ Solutions. This integration will help foster patient’s understanding of their medical care by allowing clinicians to direct patients to information on topics such as medications, conditions and procedures from beyond the point of care.

The Lexicomp Integrated Patient Education solution allows clinicians across the continuum of care to provide reliable information regarding medications, procedures, conditions, and healthy living as well as discharge instructions to patients and family members at the point of care through integration with their EMR/HIS or other healthcare applications. To accommodate the needs of an institution’s system, multiple delivery options are available, including HL7 InfoButton, APIs, web services, and flat files. By integrating this content into Emmi Solution’s patient engagement platform, clinicians can direct their patients to this same content after they have left the close care of clinical staff, offering consistency of information and helping to improve patient retention of healthcare instructions.

“As healthcare organizations seek the most efficient and effective ways to enhance patient education initiatives, the Integrated Patient Education solution coupled with a solution like EmmiEngage provides an innovative foundation for the future of healthcare delivery,” stated David Del Toro, Vice President & General Manager, Clinical Drug Information, Wolters Kluwer Health, Clinical Solutions.

“We are excited to partner with Wolters Kluwer Health,” said Devin Gross, CEO of Emmi Solutions. “Our mutual understanding of the importance of the engaged patient beyond the point of care will contribute greatly to patient knowledge, satisfaction and overall quality of care.”

About Wolters Kluwer Health

Wolters Kluwer Health is a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Serving more than 150 countries and territories worldwide, Wolters Kluwer Health’s customers include professionals, institutions and students in medicine, nursing, allied health and pharmacy. Major brands include Health Language®, Lexicomp®, Lippincott Williams & Wilkins, Medicom®, Medknow, Ovid®, Pharmacy OneSource®, ProVation® Medical and UpToDate®.

Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company. Wolters Kluwer had 2012 annual revenues of €3.6 billion ($4.6 billion), employs approximately 19,000 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Follow our official Twitter handle: @WKHealth.

About Emmi Solutions

Emmi’s proprietary interactive communication methodology delivers actionable health information to patients via multiple modalities – including computers, mobile phones and tablets – at key moments across the continuum of care. Emmi’s ability to connect with patients in language they understand at a time they are ready to learn and through the devices they already own has been demonstrated to help healthcare providers reduce costs, increase revenue and improve outcomes. The patented platform allows providers to track the delivery and consumption of information to measure the clinical and financial impact of patient engagement and meet regulatory guidelines. The web-based platform requires no installation or maintenance and can be used in stand-alone mode or fully integrated into existing systems. For more information, visit www.emmisolutions.com/. Follow us on Twitter and find us on Facebook.

 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.